Orient Europharma Co., Ltd. serves as an agent for international pharmaceutical companies.  The Company also produces a variety of milk powder, drugs, and nutritional supplements.

Announcement Of The Board Of Directors Approved
The Consolidated Financial Reports Of 2025q3.

Announcement For The Board Meeting Date Of
The 2025 Q3 Consolidated Financial Report

Announcement To Participate In The Capital
Increase By Cash Of Its Subsidiary, Op Nanopharma
Co., Ltd.

Announcement On Behalf Of Subsidiary Op Nanopharma
Co.,Ltd.For The Reference Date Of Cash Capital Increase
And Share Subscription, And Other Related Matters

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Orient Europharma (4120 TT)

Announcement Of The Board Of Directors Approved The Consolidated Financial Reports Of 2025q3.

Announcement For The Board Meeting Date Of The 2025 Q3 Consolidated Financial Report

Announcement To Participate In The Capital Increase By Cash Of Its Subsidiary, Op Nanopharma Co., Ltd.

Announcement On Behalf Of Subsidiary Op Nanopharma Co.,Ltd.For The Reference Date Of Cash Capital Increase And Share Subscription, And Other Related Matters

Announcement Of The Company'S Will Hold The Online Institutional Investor Conference On August 27, 2025

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)